RESUMEN
RESUMEN El shock cardiogénico puede complicar la evolución del infarto agudo de miocardio con elevación del segmento ST en aproximadamente el 10 % de los casos, y se asocia a elevada mortalidad. Las guías de práctica recomiendan en este contexto el empleo de dispositivos de soporte circulatorio mecánico con base en opinión de expertos o estudios no aleatorizados. Entre 2023 y 2024 se han publicado 3 ensayos clínicos aleatorizados con el empleo de ECMO o Impella, cuyos resultados y posible influencia en las guías de práctica se discuten en la presente revisión.
ABSTRACT Cardiogenic shock can complicate the course of ST-segment elevation myocardial infarction in approximately 10% of cases and is associated with high mortality. In this context, practice guidelines recommend the use of mechanical circulatory support devices based on expert opinion or non-randomized studies. Between 2023 and 2024, three randomized clinical trials using ECMO or Impella have been published. The results of these trials and their potential impact on practice guidelines are discussed in the present review.
RESUMEN
We present the case of a 34-year-old male patient with a history of Marfan syndrome who was admitted to the emergency room for acute aortic regurgitation secondary to aneurysmal dilation of the ascending thoracic aorta. In the postoperative period, post-cardiotomy cardiogenic shock was documented, so circulatory support was initiated with peripheral Veno-Arterial ECMO, which developed hypoxemia due to bacterial pneumonia and data compatible with North-South syndrome. We present a review, non-conventional cannulation strategies and a diagnostic alternative for this entity.
RESUMEN
The right ventricle is susceptible to changes in preload, afterload, and contractility. The answer is its dilation with dysfunction/acute failure; filling is limited to the left ventricle and cardiac output. Systemic venous congestion is retrograde to the right heart, it is involved in the genesis of cardiogenic shock due to right ventricle involvement. This form of shock is less well known than that which occurs due to left ventricular failure, therefore, treatment may differ. Once the primary treatment has been carried out, since no response is obtained, supportive treatment aimed at ventricular pathophysiology will be the next option. It is suggested to evaluate the preload for the reasoned indication of liquids, diuretics or even ultrafiltration. Restore or maintain heart rate and sinus rhythm, treat symptomatic bradycardia, arrhythmias that make patients unstable, use of temporary pacing or cardioversion procedures. Improving contractility and vasomotility, using vasopressors and inotropes, alone or in combination, the objective will be to improve right coronary perfusion pressure. Balance the effect of drugs and maneuvers on preload and/or afterload, such as mechanical ventilation, atrial septostomy and pulmonary vasodilators. And the increasing utility of mechanical support of the circulation that has become a useful tool to preserve/restore right heart function.
El ventrículo derecho es susceptible a cambios en la precarga, poscarga y la contractilidad y la respuesta fisiopatológica es la dilatación con disfunción/falla aguda lo que limita el llenado del ventrículo izquierdo y el gasto cardiaco. La congestión venosa sistémica, está implicada en la génesis del choque cardiogénico con compromiso del ventrículo derecho. Esta forma de choque es menos conocida que la que sucede por falla ventricular izquierda, por ende, el tratamiento puede diferir. La primera línea de tratamiento son las medidas de soporte y en caso de no funcionar, el tratamiento dirigido a la fisiopatología ventricular será la siguiente opción. Se sugiere evaluar la precarga para la indicación razonada de líquidos, diuréticos o la ultrafiltración. Restaurar o mantener la frecuencia cardiaca y el ritmo sinusal, tratar la bradicardia sintomática, las arritmias que inestabilizan a los pacientes, el uso de marcapaso temporal o procedimientos de cardioversión. Mejorar la contractilidad y vasomotilidad a través del uso de vasopresores e inotrópicos, solos o combinados, el objetivo será mejorar la presión de perfusión coronaria derecha. Balancear el efecto de fármacos y maniobras en la precarga y/o poscarga, como la ventilación mecánica, septostomía atrial y vasodilatadores pulmonares. Y la creciente utilidad del soporte mecánico de la circulación que se ha convertido en una herramienta útil para preservar/restaurar la función cardiaca derecha.
Asunto(s)
Insuficiencia Cardíaca , Choque Cardiogénico , Humanos , Choque Cardiogénico/etiología , Choque Cardiogénico/terapia , Ventrículos Cardíacos , Respiración Artificial , Gasto CardíacoRESUMEN
Objectives: Veno-arterial Extracorporeal membrane oxygenation (VA ECMO) is a salvage intervention in patients with cardiogenic shock (CS), and cardiac arrest (CA) refractory to standard therapies. The design of ECMO Teams has achieved the standardization of processes, although its impact on survival and prognosis is unknown. Objective: We aimed to analyze whether the creation of an ECMO Team has modified the prognosis of patients undergoing VA ECMO for refractory CS or CA. Materials and methods: . We conducted a single-center retrospective cohort study. Patients with refractory CS or CA who underwent VA ECMO were divided in two consecutive periods: from 2014 to April 2019 (pre-ECMO T) and from May 2019 to December 2022 (Post ECMO T). The main outcomes were survival on ECMO, in-hospital survival, complications, and annual ECMO volume. Results: Eighty-three patients were included (36 pre-ECMO T and 47 post-ECMO T). The mean age was 53 +/-13 years. The most common reason for device indication was different: postcardiotomy shock (47.2%) pre-ECMO T and refractory cardiogenic shock (29.7%) post-ECMO T. The rate of extracorporeal cardiopulmonary resuscitation was 14.5%. The median duration of VA ECMO was longer after ECMO team implementation: 8 days (IQR 5-12.5) vs. five days (IQR 2-9, p=0.04). Global in-hospital survival was 45.8% (38.9% pre-ECMO T vs. 51.1% post-ECMO T; p=0.37), and the survival rate from VA ECMO was 60.2% (55.6% pre-ECMO T vs 63.8% post-ECMO T; p= 0.50). The volume of VA ECMO implantation was significantly higher in the post-ECMO team period (13.2 +/3.5 per year vs. 6.5 +/-3.5 per year, p: 0.02). The rate of complications was similar in both groups. Conclusions: After the implementation of an ECMO team, there was no statistical difference in the survival rate of patients treated with VA ECMO. However, a significant increase in the number of patients supported per year was observed after the implementation of this multidisciplinary team. Post-ECMO T, the most common reason for device indication was cardiogenic shock, with longer run times and a higher rate of extracorporeal cardiopulmonary resuscitation.
RESUMEN
RESUMEN Introducción: el choque cardiogénico es la forma más grave de insuficiencia cardíaca aguda y la principal causa de muerte en pacientes con infarto agudo de miocardio. Objetivo: caracterizar a los pacientes con choque cardiogénico por síndrome coronario agudo en el servicio de cardiología de Las Tunas en el período octubre de 2017 a junio de 2021. Métodos: se realizó un estudio descriptivo y transversal con un universo de 325 pacientes y una muestra conformada de forma intencionada por 296 pacientes con el diagnóstico de insuficiencia cardíaca aguda por síndrome coronario agudo. Se estudiaron las variables edad, sexo, antecedentes patológicos personales, obesidad, tabaquismo, valvulopatías asociadas, frecuencia cardíaca, presión arterial sistólica, uso previo de fármacos, eventos adversos, variables ecocardiográficas y electrocardiográficas. Resultados: El 16,5 % de los pacientes estudiados desarrollaron choque cardiogénico; con prevalencia de la edad > 60 años (67,3 % grupo I vs. 80,3 % grupo II), el sexo masculino y los antecedentes de HTA (87,8 %). El uso previo de IECA o ARA II mostró una asociación inversamente proporcional a la presencia de choque cardiogénico (61,5 %). Ecocardiográficamente predominó la FEVI reducida (61,2 %), relación E/e´ alterada (32,6 %), velocidad de la onda S <5,4 cm/seg (42,9 %) y VFS elevados (46,9 %). Prevaleció el IMACEST (81,6 %) y la topografía anterior (51,1 %). Conclusiones: los pacientes con síndrome coronario agudo que con mayor frecuencia evolucionan al choque cardiogénico son los de edad avanzada, sin tratamiento farmacológico previo, con infartos de topografía anterior y fracción de eyección del ventrículo izquierdo reducida.
ABSTRACT Introduction: cardiogenic shock is the most severe form of acute heart failure and the main cause of death in patients with acute myocardial infarction. Objective: to characterize patients with cardiogenic shock due to acute coronary syndrome in the cardiology service of Las Tunas in the period October 2017 to June 2021. Methods: a descriptive and cross-sectional study was carried out with a universe of 325 patients and a sample intentionally formed by 296 patients with the diagnosis of acute heart failure due to acute coronary syndrome. The variables studied were age, sex, personal pathological history, obesity, smoking, associated valvulopathies, heart rate, systolic blood pressure, previous drug use, adverse events, echocardiographic and electrocardiographic variables. Results: 16,5 % of the patients studied developed cardiogenic shock; age > 60 years (67,3 % group I vs. 80,3 % group II), male sex and history of HT (87,8 %) prevailed. Previous use of ACEI or ARA II showed an inversely proportional association with the presence of cardiogenic shock (61,5 %). Echocardiographically, reduced LVEF (61,2 %), altered E/e' ratio (32,6 %), S-wave velocity <5,4 cm/sec (42,9 %) and elevated SFV (46,9 %) predominated. STEMI (81,6%) and anterior topography (51,1%) prevailed. Conclusions: patients with acute coronary syndrome who most frequently progress to cardiogenic shock are those of advanced age, without previous pharmacological treatment, with anterior topography infarctions and reduced left ventricular ejection fraction.
RESUMEN
SUMMARY Severe Acute Respiratory Syndrome Coronavirus 2 is part of the Cononaviridae family and is the causative agent of the 2019 (Covid-19) Coronavirus pandemic declared by the World Health Organization in March, 2020. This virus has a high rate of transmission, affecting several individuals, and has caused thousands of deaths. The clinical manifestations of Severe Acute Respiratory Syndrome Coronavirus 2 infection are not restricted only to the respiratory tract, and there is an express involvement of the cardiovascular system with a higher risk of death in this group. In such patients there is an overactivation of renin-angiotensin-aldosterone system, which promotes an increase in the expression of angiotensin-converting enzyme - 2 that acts as a receptor for the SPIKE protein expressed by the virus and enables the interaction between the host cell and Severe Acute Respiratory Syndrome Coronavirus 2. This process of infection causes a hyperinflammatory state that increases the inflammatory markers of cardiac injury. Hence, an adequate understanding and clinical guidance regarding the monitoring, and controlling the damage in these patients is essential to avoid worsening of their clinical condition and to prevent death.
Asunto(s)
Humanos , Sistema Cardiovascular , COVID-19 , Sistema Renina-Angiotensina , Pandemias , SARS-CoV-2RESUMEN
Abstract Background There has been an increase in the number of cases of Takotsubo syndrome (TTS) and of scientific publications on the theme over the last years. However, little is known about the status of this disease in Brazilian hospitals. Objective To assess mortality and major adverse cardiovascular events (MACE) during hospitalization and follow-up of TTS patients seen in a tertiary hospital in Brazil. Methods This was a retrospective, observational study on 48 patients. Clinical data, signs and symptoms, complementary tests, MACE and all-cause mortality were assessed on admission and during follow-up. Kaplan-Meier curves were used for analysis of all-cause mortality and risk for MACE at median follow-up. The 95% confidence interval was also calculated for a significance level of 5%. Results Mean age of patients was 71 years (SD±13 years), and most patients were women (n=41; 85.4%). During hospitalization, four patients (8.3%) died and five (10.4%) developed MACE. At median follow-up of 354.5 days (IQR of 81.5-896.5 days), the risk of all-cause mortality and MACE was 11.1% (95% CI= 1.8-20.3%) and 12.7% (95% CI= 3.3-22.3%), respectively. Conclusion TTS was associated with high morbidity and mortality rates in a tertiary hospital in Brazil, which were comparable to those observed in acute coronary syndrome. Therefore, the severity of TTS should not be underestimated, and new therapeutic strategies are required. Int J Cardiovasc Sci. 2020; [online].ahead print, PP.0-0
Asunto(s)
Humanos , Masculino , Femenino , Persona de Mediana Edad , Anciano , Anciano de 80 o más Años , Cardiomiopatía de Takotsubo/complicaciones , Cardiomiopatía de Takotsubo/diagnóstico , Estudios Retrospectivos , Morbilidad , Síndrome Coronario Agudo/complicaciones , Cardiomiopatía de Takotsubo/mortalidad , Cardiomiopatía de Takotsubo/epidemiología , HospitalizaciónRESUMEN
ABSTRACT Background: Cardiogenic shock (CS) is uncommon in the cardiac catheterization laboratory (CCL) among patients undergoing coronary angiography. Periprocedural CS is more frequent in high-risk patients and in technically demanding procedures. Aim: To describe the clinical outcomes of patients who underwent peripheral venoarterial extracorporeal membrane oxygenation (pVA-ECMO) for CS associated with interventional cardiology procedures. Material and Methods: Review of clinical records of seven patients treated between January 2014 and October 2018. Results: pVA-ECMO was implanted within 6 hours of the interventional cardiology procedure. All patients had coronary artery disease and one of them also had symptomatic severe aortic stenosis. One patient entered the CCL in cardiac arrest. Percutaneous coronary intervention (PCI) was performed in all patients; four patients underwent an emergency procedure and five patients experienced PCI complications. One patient undergoing transcatheter aortic valve replacement suffered acute severe aortic regurgitation. An intra-aortic balloon pump was inserted at the CCL in five patients. Six patients experienced cardiac arrest. Mean SAVE score was -4.3 and baseline lactate 55 mg/dl. pVA-ECMO mean duration was 5 ± 4 days. Survival after both hospital discharge and 12 months of follow-up was 85.7% Regarding vascular access complications, we observed one access site hematoma and one episode of cannulation site bleeding requiring surgical repair. Conclusions: pVA-ECMO should be considered in patients with periprocedural CS as a bridge to recovery. Its use was associated with improved clinical outcomes in this series.
Antecedentes: El shock cardiogénico (SC) es infrecuente en el laboratorio de cateterismo cardíaco (LCC) entre pacientes que son sometidos a coronariografía. El SC peri-procedimiento es más frecuente en pacientes de alto riesgo y en procedimientos técnicamente complejos. Objetivos: Describir los resultados clínicos de pacientes que fueron conectados a oxigenación con membrana extracorpórea veno-arterial periférica (ECMO-VAp) por SC peri-procedimiento de cardiología intervencional. Material y Métodos: Revisión de fichas clínicas de siete pacientes tratados en nuestro centro desde enero de 2014 a octubre de 2018. Resultados: ECMO-VAp fue utilizado dentro de las primeras 6 horas del procedimiento. Todos los pacientes tenían enfermedad coronaria y uno de ellos tenía además estenosis aórtica severa. Un paciente ingresó al LCC en paro cardíaco. Una intervención coronaria percutánea (ICP) fue realizada en todos los pacientes; 4 se realizaron procedimientos de emergencia y 5 pacientes tuvieron complicaciones de la ICP. A un paciente se le realizó un reemplazo valvular aórtico percutáneo y desarrolló una insuficiencia valvular aórtica aguda severa. Se instaló un balón de contrapulsación en el LCC en 5 pacientes. Seis pacientes tuvieron un paro cardiorrespiratorio. El valor del score de SAVE fue de -4,3 y el lactato basal 55 mg/dL. La duración media del ECMO-VAp fue 5 ± 4 días. La sobrevida al alta y a los 12 meses fue 85,7%. Como complicaciones del sitio de acceso vascular se observaron 1 hematoma y un episodio de sangrado que requirió reparación quirúrgica. Conclusiones: ECMO-VAp debería ser considerado en pacientes con SC peri-procedimiento como un puente a recuperación; su utilización estuvo asociada con mejoría de resultados clínicos en esta serie.
Asunto(s)
Humanos , Choque Cardiogénico , Oxigenación por Membrana Extracorpórea , Intervención Coronaria Percutánea , Reemplazo de la Válvula Aórtica Transcatéter , Choque Cardiogénico/terapia , Oxigenación por Membrana Extracorpórea/efectos adversos , Resultado del Tratamiento , Intervención Coronaria Percutánea/efectos adversosRESUMEN
ECMO (Extracorporeal Membrane Oxygenation) is an extracorporeal life support system in catastrophic lung failure, shock and cardiopulmonary resuscitation, in different age groups, with multiple physiologic features. When the candidate to be submitted is too unstable to be transported to a hospital with ECMO, cannulation before transfer allows stabilization and subsequent transport. The aim of this article is to review the current concepts of extracorporeal support, its indications, national and international experience, and its possible role in the SARS-Cov2 pandemic.
Asunto(s)
Humanos , Adulto , Neumonía Viral/terapia , Neumonía Viral/epidemiología , Oxigenación por Membrana Extracorpórea , Infecciones por Coronavirus/terapia , Infecciones por Coronavirus/epidemiología , PandemiasRESUMEN
We report a 55-year-old woman with a history of hypothyroidism and type 2 diabetes mellitus who consulted at the emergency room because of intermittent oppressive chest discomfort. At admission, electrocardiogram showed a complete atrioventricular block. A transthoracic echocardiogram disclosed severe left ventricular dysfunction. The patient developed cardiogenic shock that required the installation of the Impella system. An emergency coronary angiography showed an ostial occlusion of the anterior descending artery. Despite successful primary angioplasty, she persisted with refractory shock and progressive hypoxemia. A concomitant connection to the extracorporeal membrane oxygenation system (ECMO) was decided. The support of both devices allowed the stabilization of the patient and the improvement of perfusion parameters.
Asunto(s)
Humanos , Femenino , Persona de Mediana Edad , Choque Cardiogénico/terapia , Corazón Auxiliar , Disfunción Ventricular Izquierda , Oxigenación por Membrana Extracorpórea , Diabetes Mellitus Tipo 2RESUMEN
Resumen: El choque cardiogénico es la mayor catástrofe del infarto agudo al miocardio y de las cardiopatías en general. Se define como un estado en el cual el gasto cardiaco es ineficiente para perfundir y oxigenar los tejidos, por lo que se manifiesta con signos de hipoperfusión tisular y congestión capilar. Aunque las últimas guías no exijan el diagnóstico por medio de medidas hemodinámicas, el basarse sólo en lo clínico puede generar errores hasta en 30%. Las causas se dividen en isquémicas y no isquémicas, siendo la primera la más común. Pese a la aparición de nuevos dispositivos mecánicos, aunados al soporte médico, sólo se ha demostrado la mejora de los desenlaces con las terapias endovasculares.
Abstract: Cardiogenic shock (CSh) is the major catastrophe of acute myocardial infarction (AMI) and heart disease in general. It is defined as a state in which cardiac output (CO) is inefficient to perfuse and oxygenate tissues, which is why it manifests with signs of tissue hypoperfusion and capillary congestion. Although the latest guidelines do not require diagnosis with hemodynamic measures, relying only on the clinical can generate errors up to 30%. The causes are divided into ischemic (AMI) and non-ischemic, with the former being the most common. Despite the appearance of new mechanical devices, coupled with medical support, it has only shown the improvement of outcomes with endovascular therapies.
Resumo: O choque cardiológico (ChC) é a principal catástrofe do infarto agudo do miocárdio (IAM) e das cardiopatias em geral. Definida como um estado no qual o débito cardíaco (DC) é ineficiente para perfundir e oxigenar os tejidos, razão pela qual se manifiesta com sinais de hipoperfusão tecidual e congestão capilar. Embora as diretrizes mais recentes não exijam diagnóstico por meio de medidas hemodinâmicas, depender apenas da clínica pode gerar erros de até 30%. As causas são divididas em isquêmicas (IAM) e não isquêmicas, sendo a primeira a mais comum. Apesar do surgimento de novos dispositivos mecânicos aliados ao suporte médico, só demonstrou-se a melhora dos resultados com terapias endovasculares.
RESUMEN
Resumen La miocarditis es una enfermedad inflamatoria del miocardio. Las infecciones virales son la causa más común, aunque también puede deberse a reacciones de hipersensibilidad y de etiología autoinmunitaria, entre otras. El espectro clínico de la enfermedad es variado y comprende desde un curso asintomático, seguido de dolor torácico, arritmias y falla cardiaca aguda, hasta un cuadro fulminante. El término 'fulminante' se refiere al desarrollo de un shock cardiogénico con necesidad de soporte vasopresor e inotrópico o dispositivos de asistencia circulatoria, ya sea oxigenación por membrana extracorpórea o balón de contrapulsación intraaórtico. Cerca del 10 % de los casos de falla cardiaca por miocarditis corresponde a miocarditis fulminante. La miocarditis por influenza se considera una condición infrecuente; no obstante, su incidencia ha aumentado desde el 2009 a raíz de la pandemia de influenza por el virus AH1N1. Por su parte, la miocarditis por influenza de tipo B sigue siendo una condición infrecuente. Se describen aquí dos casos confirmados de miocarditis fulminante por el virus de la influenza B atendidos en un centro cardiovascular, que requirieron dispositivos de asistencia circulatoria mecánica.
Abstract Myocarditis is an inflammatory disease of the myocardium. Viral infections are the most common cause, although it can also be due to hypersensitivity reactions and autoimmune etiology, among other causes. The clinical spectrum of the disease is varied, from an asymptomatic course, followed by chest pain, arrhythmias, and acute heart failure, to a fulminant episode. The term fulminant refers to the development of cardiogenic shock with a need for vasopressor support and inotropic or assisted circulation devices either extracorporeal membrane oxygenation (ECMO) or intra-aortic counterpulsation balloon. About 10% of cases of heart failure due to myocarditis correspond to fulminant myocarditis. Influenza myocarditis has been considered an infrequent condition. However, its incidence has increased since 2009 as a result of the AH1N1 pandemic; otherwise, myocarditis due to the Influenza type B virus remains an infrequent entity. We describe the experience in a cardiovascular center of two confirmed cases of fulminant myocarditis due to influenza B that required circulatory assistance devices.
Asunto(s)
Femenino , Humanos , Persona de Mediana Edad , Adulto Joven , Virus de la Influenza B , Choque Cardiogénico/etiología , Gripe Humana/complicaciones , Miocarditis/etiología , Antivirales/uso terapéutico , Virus de la Influenza B/aislamiento & purificación , Derrame Pericárdico/etiología , Choque Cardiogénico/tratamiento farmacológico , Choque Cardiogénico/terapia , Vasoconstrictores/uso terapéutico , Oxigenación por Membrana Extracorpórea , Hemofiltración , Resultado Fatal , Terapia Combinada , Apoyo Vital Cardíaco Avanzado , Urgencias Médicas , Gripe Humana/tratamiento farmacológico , Gripe Humana/virología , Oseltamivir/uso terapéutico , Lesión Renal Aguda/etiología , Lesión Renal Aguda/terapia , Contrapulsador Intraaórtico , Miocarditis/diagnóstico por imagenRESUMEN
Background: Although new studies and guidelines can be considered useful tools, it does not necessarily mean they are put into clinical practice. Objective: The aim of the current analysis was to assess the changes in primary percutaneous coronary intervention (PCI) and mortality in a tertiary university hospital in southern Brazil during a six-year period .Methods: We have included consecutive patients with ST-elevation myocardial infarction (STEMI) who underwent primary PCI between March 2011 and February 2017. Previous clinical history, characteristics of the procedure, and reperfusion strategies were collected. In-hospital, short and long-term mortalities were also evaluated. The significance level adopted for all tests was 5%. Results: There was an increase in the use of radial access in patients from 20.0% in 2011 to 62.7% in 2016 (ptrend < 0.0001). Moreover, thrombus aspiration decreased significantly from 66.7% in 2011 to less than 3.0% in 2016 (ptrend < 0.0001). In-hospital, short and long-term mortalities remained reasonably stable from 2011 to 2016 (ptrend > 0.05). However, a lower in-hospital mortality was observed in patients treated through radial access (p < 0.001). Cardiogenic shock occurred in 11.1%, without statistical differences in the period (ptrend = 0.39), while long-term mortality rate decreased from 80.0% in 2011 to 27.3% in 2016 in this patient group (ptrend = 0.29). Conclusions: During a 6-year follow-up period, primary PCI characteristics underwent important modifications. Radial access became widely used, with a decrease in mortality with the use of this route, while aspiration thrombectomy became a rare procedure. The incidence of cardiogenic shock remained stable, but has shown a reduction in its mortality